|
Dec 29
|
Corcept loses patent spat against Teva, shares tumble
|
|
Dec 29
|
UPDATE 2-Corcept loses patent spat against Teva, shares tumble
|
|
Dec 28
|
Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 26
|
HSBC Sees Opportunity in These 2 Biopharma Giants Ahead of the 2024 Elections
|
|
Dec 21
|
Here’s Why Teva Pharmaceutical Industries Limited (TEVA) Rose in Q3
|
|
Dec 15
|
My 5 Largest Portfolio Holdings for 2024
|
|
Dec 14
|
Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
|
|
Dec 7
|
FTC warns pharma companies on excessive drug patenting
|
|
Dec 6
|
New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity
|
|
Nov 30
|
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
|
|
Nov 27
|
Teva Pharmaceutical upgraded to 'Buy' at UBS
|
|
Nov 27
|
Roku upgraded, Lucid Group downgraded: Wall Street's top analyst calls
|
|
Nov 27
|
Teva Pharmaceutical: Long-Term Cash Cow
|
|
Nov 27
|
Midday movers: Affirm, Amazon, and More
|
|
Nov 27
|
Roku raised to Buy, YPF extends gains following upgrade: 4 big analyst picks
|
|
Nov 17
|
Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.
|
|
Nov 16
|
50 Most Populated Countries in 2030
|
|
Nov 14
|
Alkermes (ALKS) Proprietary Drugs Aid Growth Amid Competition
|
|
Nov 14
|
TEVA, Royalty Pharma Sign Funding Deal for Schizophrenia Drug
|
|
Nov 13
|
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
|